- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07531836
Multicomponent Prehabilitation in Older Adults With Breast Cancer (PREHAB-BC65)
Effectiveness of a Multicomponent Prehabilitation Program Combined With Biomarker Characterization in Older Adults With Breast Cancer
Older adults with breast cancer frequently present with frailty, decreased functional reserve, and increased risk of postoperative complications. Prehabilitation programs have emerged as a promising strategy to improve physical function and clinical outcomes; however, evidence in geriatric oncology remains limited, particularly regarding the role of biological markers in predicting response to such interventions.
This study aims to evaluate the effectiveness of a multicomponent prehabilitation program in older adults with breast cancer, focusing on functional status, clinical outcomes, and quality of life. In addition, the study seeks to characterize biological markers associated with frailty and treatment response, with the goal of identifying potential predictors of benefit from prehabilitation.
Participants will undergo a structured prehabilitation intervention including physical exercise, nutritional optimization, and comprehensive geriatric assessment. Clinical, functional, and biomarker data will be collected longitudinally.
The results of this study may contribute to improving personalized care strategies in geriatric oncology and to identifying patients who are most likely to benefit from prehabilitation programs.
Study Overview
Status
Conditions
Detailed Description
This study is a prospective, randomized, controlled, single-blind clinical trial designed to evaluate the effectiveness of a multicomponent prehabilitation program in older adults with breast cancer, incorporating biological characterization to explore predictors of treatment response.
The trial will be conducted at the Navarre University Hospital (Pamplona, Spain). A total of 90 ambulatory patients aged 65 years or older with a confirmed diagnosis of breast cancer will be recruited and randomly assigned in a 1:1:1 ratio to usual care, a home-based multicomponent exercise program based on the Vivifrail methodology, or a supervised hospital-based intervention.
All participants will undergo baseline frailty screening followed by a comprehensive geriatric assessment to characterize functional, cognitive, nutritional, and clinical status. Assessments will be repeated at predefined time points throughout the perioperative period and during follow-up.
The intervention is structured into preoperative and postoperative phases and includes individualized multicomponent exercise, nutritional optimization, and targeted management of geriatric syndromes. The hospital-based intervention consists of supervised sessions over eight weeks, while the home-based intervention is adapted to baseline functional status.
Clinical, functional, and biological data will be collected longitudinally to evaluate the impact of the intervention and to identify predictors of clinical outcomes and treatment response.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marta Lorente Escudero, MD
- Phone Number: +34 648148503
- Email: marta.lorente.escudero@navarra.es
Study Contact Backup
- Name: Nicolás Martínez Velilla, PhD
- Phone Number: +34 670900434
- Email: nicolas.martinez.velilla@navarra.es
Study Locations
-
-
Navarre
-
Pamplona, Navarre, Spain, 31008
- Recruiting
- Hospital Universitario de Navarra
-
Contact:
- Marta Lorente Escudero, MD
- Phone Number: +34 648148503
- Email: marta.lorente.escudero@navarra.es
-
Contact:
- Nicolás Martínez Velilla, MD, PhD
- Phone Number: +34 670900434
- Email: nicolas.martinez.velilla@navarra.es
-
Principal Investigator:
- Nicolás Martínez Velilla, MD, PhD
-
Sub-Investigator:
- Bernardo Abel Cedeño Veloz, MD, PhD
-
Sub-Investigator:
- Susana de la Cruz Sánchez, MD
-
Sub-Investigator:
- Sara Esteban Gordillo, MD
-
Sub-Investigator:
- Natalia Moras Pérez, MD
-
Sub-Investigator:
- Fabricio Zambom Ferraresi, PhD
-
Sub-Investigator:
- Marta Lorente Escudero, MD
-
Sub-Investigator:
- Lucía Lozano Vicario, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥65 years
- Diagnosis of cancer requiring elective surgery with curative intent
- Candidate for prehabilitation program before surgery
- Ability to walk (with or without assistive devices)
- Ability to provide informed consent
Exclusion Criteria:
- Urgent or emergency surgery
- Severe cognitive impairment precluding participation in the intervention
- Severe functional dependency (e.g., bedridden patients)
- Medical contraindication to physical exercise
- Life expectancy <3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual Care
Participants receive standard clinical care according to routine practice, including management by oncology and surgical teams.
Identified geriatric conditions are communicated to the treating physician for appropriate management.
|
|
|
Experimental: Home-based Multicomponent Prehabilitation (Vivifrail)
Participants perform a home-based multicomponent exercise program based on the Vivifrail methodology, including strength, endurance, balance, and flexibility training.
The program is tailored according to baseline functional status and supported by caregiver supervision.
Participants also receive comprehensive geriatric assessment and nutritional optimization.
|
Participants perform a structured home-based multicomponent exercise program based on the Vivifrail methodology, including strength, endurance, balance, and flexibility training.
The program is individualized according to baseline functional status.
Participants undergo comprehensive geriatric assessment with targeted interventions including nutritional optimization, medication review, and management of geriatric syndromes.
|
|
Experimental: Supervised Multicomponent Prehabilitation
Participants receive a supervised multicomponent exercise program delivered in the hospital setting, including aerobic, resistance, balance, and flexibility training over eight weeks.
The intervention is combined with comprehensive geriatric assessment, nutritional optimization, and individualized management of geriatric syndromes.
|
Participants undergo comprehensive geriatric assessment with targeted interventions including nutritional optimization, medication review, and management of geriatric syndromes.
Participants receive a structured, supervised multicomponent exercise program delivered in a hospital setting, including aerobic, strength, balance, and flexibility training over eight weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in physical function assessed by Short Physical Performance Battery (SPPB)
Time Frame: Baseline to 8 weeks (end of prehabilitation program)
|
Physical function will be assessed using the Short Physical Performance Battery (SPPB), a validated tool in older adults (score range 0-12, higher scores indicate better performance).
The primary outcome will be the change in SPPB score from baseline to the end of the 8-week intervention.
|
Baseline to 8 weeks (end of prehabilitation program)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of postoperative complications
Time Frame: Within 30 days after surgery
|
Occurrence of postoperative complications within 30 days after surgery, classified according to the Clavien-Dindo classification.
|
Within 30 days after surgery
|
|
Length of hospital stay
Time Frame: From date of surgery until hospital discharge, with a maximum follow-up of 30 days postoperatively
|
Number of days from surgery to hospital discharge.
|
From date of surgery until hospital discharge, with a maximum follow-up of 30 days postoperatively
|
|
Functional decline after surgery
Time Frame: Baseline to 30 days after surgery
|
Functional decline defined as a decrease in the Short Physical Performance Battery (SPPB) score (range 0 to 12, with higher scores indicating better physical performance) or loss of independence in activities of daily living compared to baseline.
|
Baseline to 30 days after surgery
|
|
Health-related quality of life
Time Frame: Baseline to 8 weeks and 30 days post-surgery
|
Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; scores transformed to a 0-100 scale, where higher scores indicate better functioning or worse symptoms depending on the domain).
|
Baseline to 8 weeks and 30 days post-surgery
|
|
Adherence to the intervention
Time Frame: During the 8-week intervention period
|
Percentage of prescribed exercise sessions completed by participants.
|
During the 8-week intervention period
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Marta Lorente Escudero, MD, Navarre Health Service (SNS-O), Navarre University Hospital (HUN), Pamplona, Spain
Publications and helpful links
General Publications
- Welch SA,Ward RE,Beauchamp MK,Leveille SG,Travison T,Bean JF
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Neuromuscular Manifestations
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Pathological Conditions, Anatomical
- Skin Diseases
- Breast Diseases
- Muscular Atrophy
- Atrophy
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Frailty
- Breast Neoplasms
- Sarcopenia
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Population Characteristics
- Health Status
- Demography
- Epidemiologic Measurements
- Geriatric Assessment
Other Study ID Numbers
- HUN-PREHAB-BC-65
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Home-based Multicomponent Prehabilitation (Vivifrail)
-
Fundacion Miguel ServetHospital Universitario Getafe; Matia FoundationUnknownCognitive Impairment | Frail Elderly SyndromeSpain
-
China Medical University HospitalCompletedFrailty | Aging | Physical InactivityTaiwan
-
European University SpainPublic Health Service of MadridNot yet recruiting
-
Elena Pérez Expósito, MDNot yet recruiting
-
Nicole HildebrandUniversity Medical Center Groningen; University of Turin, ItalyCompletedCancer | Weight, Body | Cancer of Pancreas | Aerobic Capacity | Preoperative Physical Exercise Training | Aerobic Fitness | Functional MobilityNetherlands, Italy
-
Montreal Heart InstituteCompletedNeurodegenerative Diseases | Primary Progressive Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Non-fluent AphasiaCanada
-
University of Bari Aldo MoroCompleted
-
Queen's UniversitySt. Joseph's Healthcare Hamilton; Ottawa Hospital Research Institute; Canadian... and other collaboratorsNot yet recruitingPostoperative Complications | Surgical Procedures, Operative | Preoperative Care | Prehabilitation | Elective Surgical ProceduresCanada
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalNot yet recruitingCancer Rehabilitation | Lymphedema Arm | Breast Cancer (Early Breast Cancer) | Postoperative Shoulder DysfunctionTurkey (Türkiye)
-
Fundacion Universitaria Maria CanoUniversidad Iberoamericana A.C., MexicoCompletedMultiple ComorbidityColombia